Eligio Miccichè (@eligioal) 's Twitter Profile
Eligio Miccichè

@eligioal

Cardiovascular interventionist - Humanitas Gavazzeni - Bergamo

ID: 1379132672346296323

calendar_today05-04-2021 18:04:02

39 Tweet

94 Followers

199 Following

Eligio Miccichè (@eligioal) 's Twitter Profile Photo

78 YO lady, former smoker, CKD IV stage (recent CVVHD), multifactorial anemia, frail 2019 cystectomy with ureter-ileo anastomosis Recent admission for sepsis During the stay --> NSTEMI and LVEF 30 %, anterior wall septum and apex hypokinesia. How would you treat this patient?

Francesco Condello (@fracond_94) 's Twitter Profile Photo

Long RCA disease with distal subocclusion efficacely treated with hybrid approach (stenting plus DCB) and enrolled in HYPER II study at Humanitas Gavazzeni. #HybridApproach #DCB #DrugCoatedBalloon #HYPERII #RestoreDCB #Longdisease Davide Cao Eligio Miccichè

Davide Capodanno (@dfcapodanno) 's Twitter Profile Photo

Next stop in the STEMI with multivessel disease saga: the BIOVASC trial, presented later today at #ACC23, will try to address the remaining question of timing of complete revascularization: immediate or staged? If you are lost with the several trial combinations, here is a recap.

Next stop in the STEMI with multivessel disease saga: the BIOVASC trial, presented later today at #ACC23, will try to address the remaining question of timing of complete revascularization: immediate or staged? If you are lost with the several trial combinations, here is a recap.
Davide Capodanno (@dfcapodanno) 's Twitter Profile Photo

Can we agree that CCTA serves to rule out CAD and not to rule in subcritical lesions which seem critical to the non-interventional cardiologist because the radiologist reports them as areas and not as diameters? And let's stop prescribing CCTA for no reason, while we're at it.

Can we agree that CCTA serves to rule out CAD and not to rule in subcritical lesions which seem critical to the non-interventional cardiologist because the radiologist reports them as areas and not as diameters? And let's stop prescribing CCTA for no reason, while we're at it.
Syed Ali Naqvi (@syedynaqvi1) 's Twitter Profile Photo

Nice study. Eruptive calcified nodule has worse TLF at 2 years than non-eruptive calcified nodule. "The calcified nodule paradox" is the title of the editorial! From JACC Journals jacc.org/doi/10.1016/j.…

Nice study. Eruptive calcified nodule has worse TLF at 2 years than non-eruptive calcified nodule. "The calcified nodule paradox" is the title of the editorial!

From <a href="/jaccjournals/">JACC Journals</a> jacc.org/doi/10.1016/j.…
Davide Capodanno (@dfcapodanno) 's Twitter Profile Photo

Calcified nodules are characterised by distinct histological and morphological features. There is no consensus on whether these characteristics can influence the applicability, efficacy and outcomes of calcium modification strategies and PCI. A debate. eurointervention.pcronline.com/article/all-ca…

Calcified nodules are characterised by distinct histological and morphological features. There is no consensus on whether these characteristics can influence the applicability, efficacy and outcomes of calcium modification strategies and PCI. A debate. eurointervention.pcronline.com/article/all-ca…
Marco Barbanti (@barbanti_marco) 's Twitter Profile Photo

New evidence on coronary revascularization in TAVI setting from the REVASC-TAVI Registry: should we pospone PCI after TAVI? EuroIntervention eurointervention.pcronline.com/article/compar…

Davide Capodanno (@dfcapodanno) 's Twitter Profile Photo

Three notable class 3 recommendations against routine periodic testing in asymptomatic CCD patients from AHA/ACC guidelines: 1) no benefit with coronary CTA or stress testing 2) no benefit of periodic assessment of LVEF 3) harm with coronary angiography jacc.org/doi/10.1016/j.…

Three notable class 3 recommendations against routine periodic testing in asymptomatic CCD patients from AHA/ACC guidelines:
1) no benefit with coronary CTA or stress testing 
2) no benefit of periodic assessment of LVEF
3) harm with coronary angiography
jacc.org/doi/10.1016/j.…
Davide Capodanno (@dfcapodanno) 's Twitter Profile Photo

After 10 years to complete it, the DanGer-SHOCK trial showed that the routine use of a microaxial flow pump with standard care in the treatment of patients with STEMI-related cardiogenic shock led to a lower risk of death from any cause at 180 days than standard care alone. The

After 10 years to complete it, the DanGer-SHOCK trial showed that the routine use of a microaxial flow pump with standard care in the treatment of patients with STEMI-related cardiogenic shock led to a lower risk of death from any cause at 180 days than standard care alone. 

The
Davide Capodanno (@dfcapodanno) 's Twitter Profile Photo

Intravascular and intracardiac masses are usually represented by thrombi, tumours, and vegetations. Traditionally, their treatment is surgical or, in some circumstances, based on systemic anticoagulation or fibrinolysis. This review summarises the clinical results of different

Intravascular and intracardiac masses are usually represented by thrombi, tumours, and vegetations. Traditionally, their treatment is surgical or, in some circumstances, based on systemic anticoagulation or fibrinolysis. This review summarises the clinical results of different